UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,111 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in MaxCyte, Inc. (NASDAQ:MXCT) by 11.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 203,648 shares of the company’s stock after selling 27,111 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.19% of MaxCyte worth $792,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in MXCT. Marshall Wace LLP purchased a new stake in shares of MaxCyte in the 2nd quarter worth about $1,959,000. Mudita Advisors LLP boosted its stake in MaxCyte by 5.6% during the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after acquiring an additional 167,101 shares in the last quarter. Royce & Associates LP grew its holdings in MaxCyte by 59.8% in the third quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock worth $1,260,000 after purchasing an additional 121,272 shares during the period. Dimensional Fund Advisors LP grew its holdings in MaxCyte by 13.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after purchasing an additional 121,090 shares during the period. Finally, River Global Investors LLP increased its stake in shares of MaxCyte by 4.7% during the third quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock valued at $8,034,000 after purchasing an additional 93,340 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Down 1.2 %

Shares of MXCT opened at $4.14 on Friday. The stock has a market cap of $437.56 million, a P/E ratio of -12.18 and a beta of 1.37. The business’s 50 day moving average price is $3.74 and its 200-day moving average price is $4.06. MaxCyte, Inc. has a 52 week low of $3.16 and a 52 week high of $5.55.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. On average, equities analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current year.

Insider Buying and Selling

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now directly owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. The trade was a 7.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 27,607 shares of company stock worth $102,782 in the last quarter. Corporate insiders own 3.00% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.